HC Wainwright & Co. Reiterates Neutral on NovoCure, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on NovoCure (NASDAQ:NVCR) and maintained a $22 price target.
June 04, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on NovoCure and maintained a $22 price target.
The reiteration of a Neutral rating and maintenance of the $22 price target suggests that the analyst does not foresee significant short-term changes in NovoCure's stock price. This neutral stance indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100